The real impact of the IRA drug price controls

Cost savings for seniors are real—but there are thousands of ways to squeeze the balloon. 

Christopher Kerns
Christopher Kerns
Updated Jul 19, 2024 11 min read

Cost savings for seniors are real—but there are thousands of ways to squeeze the balloon

When the Inflation Reduction Act passed in 2022, much ink was spilled on its provisions for controlling drug prices, allowing Medicare to begin negotiating (i.e., setting) prices for on-patent, branded pharmaceuticals well before their patents have expired (with some exceptions; more on that in a moment). Well now we have the first 10 drugs subject to negotiation, which will swell to a total of 60 by 2029.

When the law was passed last year, I was skeptical about the drug price provisions. Wasn’t Big Pharma so powerful that such controls could never make it to any president’s desk? Or did the drugmakers have a different master plan, one not obvious to casual observers? After speaking to life science executives and lobbyists, I’m here to confirm that, no, the IRA drug provisions were not part of some corporate cabal’s master plan. Quite simply, the drugmakers lost that lobbying battle, an event so exceedingly rare that it was met with incredulity nearly everywhere (including from yours truly, at first). But they don’t intend to keep losing. And that’s why I find the praise and laments generated by the release of the first 10 drugs on the list so…unhelpful. In case you haven’t been following the rhetoric on the IRA’s drug price negotiation provisions, I can sum it up quickly:

Let’s talk.

Questions? Want to learn more about what Union can do for you? We’d love to hear from you.